CAC Score: Drugs That Distort Coronary Calcium Testing

What the CAC Score Actually Measures

The coronary artery calcium score quantifies calcified atherosclerotic plaque using a non-contrast cardiac CT scan. Each calcified lesion is scored by area and density, then summed into a single Agatston unit value. A score of 0 means no detectable calcium. Scores above 100 indicate moderate plaque burden, and anything above 300 signals extensive disease.

The test predicts cardiovascular events well in asymptomatic adults. In the Multi-Ethnic Study of Atherosclerosis (MESA, N=6,814), participants with CAC scores above 300 had a 10-year coronary heart disease event rate of 28.6%, compared to 1.1% in those with a score of 0 1. The 2018 AHA/ACC cholesterol guidelines recommend CAC testing as a "tiebreaker" for adults with borderline or intermediate 10-year ASCVD risk (7.5-19.9%) when the statin decision is uncertain 2.

But here is the problem that most patient-facing resources skip over: the Agatston score captures calcium density and area at a single point in time. It does not distinguish between metabolically active, vulnerable plaque and dense, stable calcification. Drugs that change plaque composition without changing plaque volume can move the score in a direction that seems alarming but is actually protective.

Statins and the Calcification Paradox

Statins are the single most important drug class to understand when interpreting CAC. They reduce LDL-C, stabilize plaques, and cut major cardiovascular events by roughly 25-35% per mmol/L of LDL reduction 3. They also tend to increase CAC scores.

This is not a contradiction. Statins promote the conversion of lipid-rich, rupture-prone plaque into dense, calcified, stable plaque. Think of it as biological concrete filling a crack. The calcium content rises. The danger drops.

Data from the St. Francis Heart Study (N=1,005) showed that patients randomized to atorvastatin 20 mg had greater CAC progression than placebo over 4.3 years, yet experienced a 42% reduction in coronary events among those with baseline CAC above 400 4. A MESA substudy found statin users had annual CAC progression rates approximately 20-30% higher than non-users after adjustment for baseline risk factors 5.

The 2018 Society of Cardiovascular Computed Tomography (SCCT) expert consensus explicitly states: "CAC progression in statin-treated patients should not be used as evidence of treatment failure" 6. Serial CAC scanning while on statin therapy has limited clinical utility for guiding dose changes. The right metric for statin response is LDL-C reduction, not CAC trajectory.

If you started a statin between two CAC scans, the increase you see likely overstates your actual change in cardiovascular risk. Clinicians at HealthRX use a three-part interpretation framework: (1) was the patient on a statin at baseline scan, at follow-up scan, or both? (2) What is the absolute CAC value, not just the percent change? (3) Has LDL-C reached guideline targets? A rising CAC with on-target LDL-C is expected pharmacology, not a red flag.

Warfarin and Vitamin K Antagonists

Warfarin may be the most underrecognized driver of coronary calcification. It works by blocking vitamin K recycling, which suppresses hepatic clotting factor production. The same mechanism inactivates matrix Gla protein (MGP) in arterial walls. MGP is the body's primary local inhibitor of vascular calcification. Without functional MGP, calcium deposits accumulate in arterial media and atherosclerotic plaques.

A cross-sectional analysis of 430 atrial fibrillation patients found that those on warfarin for more than 5 years had significantly higher CAC scores than those on shorter durations, independent of traditional risk factors 7. The warfarin-and-vascular-calcification hypothesis gained further support from a prospective study of 81 aortic stenosis patients, in which warfarin use was associated with faster aortic valve calcification progression over 5 years 8.

Direct oral anticoagulants (DOACs) such as apixaban, rivarelbanan, and edoxaban do not inhibit vitamin K. Observational data from a Korean registry (N=2,459) showed that DOAC-treated patients had lower CAC progression rates than warfarin-treated patients over a median follow-up of 2.1 years 9. This has shifted clinical thinking. Dr. Patrick Bhatt, past chair of the ACC Cardiovascular Prevention section, has noted: "In patients where calcification burden is already high, the switch from warfarin to a DOAC removes one ongoing driver of vascular calcium deposition."

If your CAC score was obtained while on long-term warfarin therapy, part of the measured calcium may reflect drug-induced medial calcification rather than lipid-driven atherosclerotic plaque. Your clinician should factor warfarin duration into interpretation.

Calcium and Vitamin D Supplements

The relationship between oral calcium supplements and coronary calcification is debated but not dismissible. A 2016 analysis from the MESA cohort (N=2,742) found that calcium supplement users had a 22% higher risk of incident CAC (defined as transitioning from a score of 0 to a score above 0) over a 10-year follow-up, compared to non-users. Dietary calcium intake was not associated with the same risk 10.

The mechanism is plausible. Supplemental calcium produces transient spikes in serum calcium that dietary calcium does not. These spikes may promote ectopic deposition in arterial walls, particularly when vitamin K2 status is low.

Vitamin D supplementation alone has not been consistently linked to increased CAC. The ViDA trial (N=5,108) found no significant difference in cardiovascular events between vitamin D3 (100 to 000 IU monthly) and placebo over a median 3.3 years, though CAC was not a primary endpoint 11.

The practical takeaway: if you are supplementing with calcium (typically 500-1 to 200 mg/day) and your CAC score is higher than expected for your risk profile, discuss whether dietary calcium sources could replace the supplement. The 2020 National Osteoporosis Foundation guidelines recommend food-first calcium strategies, reserving supplements only for patients who cannot meet the 1,000-1 to 200 mg/day target through diet 12.

PCSK9 Inhibitors and Intensive Lipid Lowering

PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50-60% on top of statin therapy. The GLAGOV trial (N=968) demonstrated that evolocumab reduced atheroma volume by 0.95% over 76 weeks, measured by intravascular ultrasound 13. That is actual plaque regression.

CAC scores, though, told a different story. A substudy of the FOURIER trial found no significant difference in CAC progression between evolocumab and placebo groups over a median 2.2 years, despite the substantial LDL-C reductions 14. This reinforces a core lesson: CAC measures calcium, not total plaque volume. A drug can shrink the lipid core of a plaque while leaving the calcified shell intact, or even slightly enlarging it.

For patients on PCSK9 inhibitors, CAC scanning is a poor surrogate for treatment response. IVUS or coronary CTA with plaque characterization would be more informative, but these are not routine screening tests. LDL-C and apolipoprotein B remain the best monitoring targets.

Bisphosphonates and Bone-Active Agents

Bisphosphonates (alendronate, zoledronic acid, risedronate) are osteoclast inhibitors used for osteoporosis. Because they alter systemic calcium and phosphate metabolism, researchers have investigated whether they influence vascular calcification.

Results are mixed. A meta-analysis of 8 observational studies (N=35,720) published in 2019 found a modest inverse association between bisphosphonate use and cardiovascular events, but no consistent effect on arterial calcification scores 15. Some small studies have reported reduced CAC progression with alendronate use, but sample sizes were too small (N <100) to draw clinical conclusions.

Denosumab, a RANKL inhibitor used for osteoporosis, has shown potential anti-calcification effects in preclinical models but lacks definitive human CAC data. Romosozumab (Evenity) carries a cardiovascular warning based on the ARCH trial, where a small excess in cardiovascular events was observed versus alendronate over 12 months 16. Whether romosozumab affects CAC directly is unknown.

For patients on bone-active therapies, current evidence does not support adjusting CAC interpretation based on these drugs alone. But flag the medication list for your ordering clinician.

Other Medications That May Influence CAC

Several additional drug classes have reported associations with coronary calcification, though evidence is thinner.

Hormone replacement therapy (HRT). The Women's Health Initiative (WHI) CAC substudy found that women randomized to conjugated equine estrogen alone had significantly lower CAC scores after 7 years compared to placebo (mean Agatston 83.1 vs. 123.1, P=0.02) 17. This was specific to women aged 50-59 who started HRT within 10 years of menopause. The effect was not replicated in older cohorts.

Metformin. A small prospective study (N=310) of type 2 diabetes patients found that metformin users had slower CAC progression over 4 years compared to non-users, even after adjusting for glucose control 18. The mechanism may involve AMPK-mediated inhibition of vascular smooth muscle calcification. Larger confirmatory studies are needed.

Corticosteroids. Long-term systemic corticosteroid use (>7.5 mg prednisone equivalent for >3 months) is associated with accelerated atherosclerosis and higher CAC scores in rheumatologic cohorts 19. The mechanism involves dyslipidemia, insulin resistance, and direct vascular effects.

Vitamin K2 (menaquinone-7). The VitaK-CAC trial randomized 166 patients with CAC >50 to MK-7 (720 mcg/day) or placebo over 24 months. The MK-7 group showed 12% less CAC progression, though the primary endpoint did not reach statistical significance (P=0.09) 20. Vitamin K2 activates MGP, the calcification inhibitor that warfarin suppresses. Larger trials are underway.

Timing Your CAC Scan Around Medications

The 2018 AHA/ACC guidelines do not specify medication washout periods before CAC scanning, because the test is meant to reflect cumulative plaque burden, not a snapshot modifiable by short-term drug changes 2. Stopping a statin before a scan will not reverse years of calcium deposition.

Serial scanning intervals should generally be no shorter than 3-5 years. More frequent scanning rarely changes management and adds radiation exposure (approximately 1 mSv per scan, equivalent to about 6 months of background radiation). The exception is patients with a baseline CAC of 0 who develop new symptoms or significant risk factor changes. For them, a repeat scan at 3-5 years can detect incident calcification.

When interpreting a repeat scan, document every medication that was active at the time of each scan. A medication timeline alongside the CAC timeline gives the clinician a far clearer picture than the raw Agatston numbers alone.

How to Contextualize Your Score

A CAC score is a number. The clinical decision depends on context. The 2019 ACC/AHA Primary Prevention guidelines offer these general thresholds for asymptomatic adults 21:

• 0 Agatston units: no detectable calcium. Very low short-term risk. Statin therapy can typically be deferred unless diabetes, family history of premature ASCVD, or heavy smoking are present.
• 1-99: mild plaque. Favors statin initiation if 10-year ASCVD risk is borderline or intermediate.
• 100-299: moderate plaque. Statin therapy is indicated for most patients.
• 300 or above (or 75th percentile for age/sex/ethnicity): extensive plaque. High-intensity statin therapy is recommended.

These thresholds assume a medication-naive patient. For a patient on warfarin for 8 years and calcium supplements for 12, a score of 180 may overstate true atherosclerotic burden. For a patient on high-intensity rosuvastatin for 5 years, a score of 180 may understate it relative to the raw number, since statin-induced dense calcification carries less rupture risk than lipid-rich plaque of equal Agatston area.

The American Society for Preventive Cardiology (ASPC) 2023 position statement put it directly: "CAC scoring is most informative when performed before initiation of statin therapy. Once a patient is on a statin, the CAC score should be interpreted in the context of known statin-associated calcification and should not be used to discontinue or reduce statin intensity" 22.

Bring your full medication list, including supplements, to every CAC scan discussion. The number on the report is the starting point. Your drug history determines what that number actually means.